Aprea Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aprea Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2018 to Q3 2024.
  • Aprea Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.78M, a 18.1% decline year-over-year.
  • Aprea Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$13.5M, a 1.67% decline year-over-year.
  • Aprea Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$14.3M, a 87.3% increase from 2022.
  • Aprea Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$113M, a 203% decline from 2021.
  • Aprea Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$37.1M, a 30.6% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$13.5M -$3.78M -$579K -18.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$12.9M -$3.47M -$211K -6.47% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$12.7M -$2.81M +$1.57M +35.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$14.3M -$3.44M -$1M -41% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$13.3M -$3.2M +$820K +20.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$14.1M -$3.26M +$95M +96.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$109M -$4.38M +$3.56M +44.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$113M -$2.44M +$5.31M +68.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 -$118M -$4.02M +$5.43M +57.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$123M -$98.3M -$88M -859% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$35.4M -$7.94M +$1.73M +17.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$37.1M -$7.76M +$7.64M +49.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-26
Q3 2021 -$44.8M -$9.45M +$2.87M +23.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$47.6M -$10.3M +$6.12M +37.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$53.7M -$9.67M -$268K -2.86% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$53.5M -$15.4M -$2.32M -17.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-30
Q3 2020 -$51.2M -$12.3M -$6.07M -97.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$45.1M -$16.4M -$11.1M -211% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$34M -$9.4M -$5.93M -170% Jan 1, 2020 Mar 31, 2020 10-Q 2021-08-12
Q4 2019 -$28.1M -$13.1M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-15
Q3 2019 -$6.25M -$3.11M -99.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$5.26M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$3.48M Jan 1, 2019 Mar 31, 2019 10-Q 2020-08-11
Q3 2018 -$3.14M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.